EU Sees Drop In Pay-For-Delay Deals On Generics

Law360, New York (July 6, 2011, 12:55 PM EDT) -- The European Commission released a report Wednesday showing that the use of so-called pay-for-delay settlements between brand-name drugmakers and generics companies continues to decline, dropping to 3 percent of the industry's patent settlements last year.

Out of 89 patent settlements between brand name and generic-drug makers identified by the European competition regulator in 2010, only three — or three percent — were of the type that could attract antitrust scrutiny, the EC said, noting that its 2009 review found that 10 percent of identified settlements could...
To view the full article, register now.